Pre-market hot trades in US stocks: Teradyne up 4.97% in pre-market; Sandisk up 4.94% in pre-market

Pre-market Hot Trades in US Stocks

Teradyne pre-market up 4.97%. Based on recent key news:

1. On July 25, Teradyne achieved a year-on-year revenue growth of 87.04% and a profit margin expansion of 17 percentage points despite semiconductor equipment export restrictions. AI demand outweighed the negative impact from the Chinese market, driving the stock price up.

2. On July 27, analysts pointed out that about 70% of Teradyne's revenue is related to AI, and it is expected to continue performing strongly in the second quarter earnings report on July 29. The market is full of expectations for its future performance, further boosting the stock price.

3. On July 27, strong demand for Nvidia's chips and related connectors drove growth across the entire AI industry. Teradyne, as an AI server infrastructure supplier, benefited significantly, leading to an increase in its stock price. Strong demand in the AI industry is pushing related stocks up.

Sandisk pre-market up 4.94%. Based on recent key news:

1. On July 24, Sandisk fell 5.14% during the trading session, with the storage chip sector overall weakening. Peers like Micron Technology, Western Digital, and Seagate Technology also saw declines, reflecting overall industry pressure. Source: Zhitong Finance

2. On July 24, Susquehanna analysts lowered Sandisk's target price from $3,250 to $3,050, citing revisions to financial models and uncertainties in AI storage architecture. Source: Wall Street Insight

3. On July 27, the AI data center boom drove all semiconductor stocks up, but NAND spot prices fell, leading the market to reassess the cyclical risks of AI components. Source: Jinshi Data Storage chip prices are highly volatile, putting overall industry pressure.

Top Gainers in Pre-market US Stocks

Lion Group Holding pre-market up 93.30%. Based on recent key news:

1. On July 23, HRT Financial sold 34,989 shares of Lion Group Holding, reducing its holdings to 63,695 shares. This move may raise market concerns about changes in the company's shareholder structure, potentially affecting stock price volatility. Source: EDGAR

2. On July 24, Spark analysts rated Lion Group Holding as neutral, pointing out weak financial performance and a bearish technical outlook, noting that despite being oversold, the stock price remains below key moving averages. This analysis may impact investor confidence. Source: TipRanks

3. No other significant news recently. The market holds a cautious attitude towards Lion Group Holding's financial performance.

Profusa pre-market up 82.46%. Based on recent key news:

1. On July 27, Profusa announced the appointment of Jack Stover as Executive Chairman and CEO, and plans to acquire a commercial-stage diagnostics company. This move is seen by the market as a strategic expansion, significantly boosting the stock price. Source: GlobeNewswire

2. On July 27, former CEO and Chairman Ben Hwang transitioned to President, and Liviu Goldenberg joined the board, bringing rich global leadership experience. This personnel change is believed to strengthen the company's governance structure and further boost market confidence. Source: GlobeNewswire

3. No other significant news recently. The diagnostic industry has great expansion potential, and policy changes need to be monitored.

Matinas BioPharma surged 78.83% in pre-market trading. Based on recent key news:

1. On July 23, Matinas BioPharma announced the termination of its market sales agreement with BTIG. This agreement allowed the company to issue up to $50 million in common stock through the market. After terminating the agreement, the company lost an important financing channel, which may affect its future fundraising capabilities.

2. On July 24, after BTIG terminated the sales agreement, Matinas BioPharma did not incur any termination fees or expenses. This move may be interpreted by the market as an enhancement of the company's financial stability, driving the stock price up.

3. On July 25, analysts rated Matinas BioPharma as neutral, mainly due to the company's weak financial performance and a still bearish technical outlook. Nevertheless, the market reacted positively to the company's strategic changes, leading to a significant increase in stock price. The biopharmaceutical industry has been quite volatile recently and requires attention